Literature DB >> 20435310

The Crataegus extract WS 1442 inhibits balloon catheter-induced intimal hyperplasia in the rat carotid artery by directly influencing PDGFR-beta.

Robert Fürst1, Ute Zirrgiebel, Frank Totzke, Stefan Zahler, Angelika M Vollmar, Egon Koch.   

Abstract

OBJECTIVE: Effective systemic drugs against restenosis upon percutaneous transluminal coronary angioplasty (PTCA) are largely lacking. Polyphenols have been suggested to ameliorate post-angioplasty restenosis. Hawthorn (Crataegus spp.) extracts, which are among the most frequently used herbal medicinal products against mild forms of congestive heart failure, contain polyphenols, but have not been investigated in this context. We aimed to assess the potential of the hawthorn extract WS 1442 to prevent balloon catheter-induced intimal hyperplasia and to elucidate the underlying mechanisms.
METHODS: We analyzed the effects of WS 1442 on serum-induced vascular smooth muscle cell (VSMC) and endothelial cell (EC) growth and migration, growth factor-induced proliferation, growth factor receptor activity, and neointima formation in the rat carotid artery model.
RESULTS: WS 1442 (100 microg/ml) decreased VSMC migration by 38% and proliferation by 44%, whereas EC migration and proliferation were unaltered. The extract inhibited VSMC DNA synthesis induced by platelet-derived growth factor (PDGF) (IC(50): 47 microg/ml), but not that of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). Along this line, WS 1442 blocked recombinant human PDGF receptor (PDGFR)-beta kinase activity (IC(50): 1.4 microg/ml) and decreased PDGFR-beta activation and extracellular signal-regulated kinase (ERK) activation in VSMCs. In rats, orally administered WS 1442 significantly reduced neointima formation after balloon catheter dilatation of the carotid artery.
CONCLUSION: WS 1442 inhibits migration and proliferation of VSMCs, but not of ECs, and reduces balloon catheter-evoked neointima formation probably through inhibition of PDGFR-beta. Thus, the present study suggests a novel adjunct pharmacological strategy to prevent angioplasty-related restenosis. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435310     DOI: 10.1016/j.atherosclerosis.2010.04.003

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

Review 1.  Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach.

Authors:  Jie Wang; Xingjiang Xiong; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-29       Impact factor: 2.629

2.  Protective effects of Hawthorn (Crataegus oxyacantha) extract against digoxin-induced arrhythmias in rats.

Authors:  Hayrullah Alp; Burak Cem Soner; Tamer Baysal; Ayşe Saide Şahin
Journal:  Anatol J Cardiol       Date:  2014-12-25       Impact factor: 1.596

3.  Goniolactone C, a styryl lactone derivative, inhibits PDGF-BB-induced vascular smooth muscle cell migration and proliferation via PDGFR/ERK signaling.

Authors:  Lan Sun; Rui Zhao; Xi Lan; Ruoyun Chen; Si Wang; Guanhua Du
Journal:  Molecules       Date:  2014-11-26       Impact factor: 4.411

4.  Salvianolic acid A inhibits PDGF-BB induced vascular smooth muscle cell migration and proliferation while does not constrain endothelial cell proliferation and nitric oxide biosynthesis.

Authors:  Lan Sun; Rui Zhao; Li Zhang; Tiantai Zhang; Wenyu Xin; Xi Lan; Chao Huang; Guanhua Du
Journal:  Molecules       Date:  2012-03-14       Impact factor: 4.411

5.  Crataegus Extract WS®1442 Stimulates Cardiomyogenesis and Angiogenesis From Stem Cells: A Possible New Pharmacology for Hawthorn?

Authors:  Jonas Halver; Kristin Wenzel; Jandirk Sendker; Carmen Carrillo García; Clemens A J Erdelmeier; Erik Willems; Mark Mercola; Nico Symma; Stephanie Könemann; Egon Koch; Andreas Hensel; Dennis Schade
Journal:  Front Pharmacol       Date:  2019-11-27       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.